Long-term effects of intermittent equine parathyroid hormone fragment (ePTH-1-37) administration on bone metabolism in healthy horses.

Autor: Weisrock KU; Institute of Animal Nutrition, Nutrition Diseases and Dietetics, Faculty of Veterinary Medicine, University of Leipzig, Gustav-Kuehn-Str. 8, 04159 Leipzig, Germany; Functional Genomics and Bioregulation, Institute of Animal Genetics, FLI Mariensee, Hoeltystr. 10, 31535 Neustadt a. R., Germany., Winkelsett S; Institute of Animal Nutrition, Nutrition Diseases and Dietetics, Faculty of Veterinary Medicine, University of Leipzig, Gustav-Kuehn-Str. 8, 04159 Leipzig, Germany., Martin-Rosset W; Department of Animal Sciences, INRA Center Clermont-Ferrand, 63122 Saint-Genès-Champanelle, France., Forssmann WG; IPF Pharmaceuticals GmbH, Feodor-Lynen-Str. 31, 30625 Hannover, Germany., Parvizi N; Functional Genomics and Bioregulation, Institute of Animal Genetics, FLI Mariensee, Hoeltystr. 10, 31535 Neustadt a. R., Germany., Coenen M; Institute of Animal Nutrition, Nutrition Diseases and Dietetics, Faculty of Veterinary Medicine, University of Leipzig, Gustav-Kuehn-Str. 8, 04159 Leipzig, Germany., Vervuert I; Institute of Animal Nutrition, Nutrition Diseases and Dietetics, Faculty of Veterinary Medicine, University of Leipzig, Gustav-Kuehn-Str. 8, 04159 Leipzig, Germany. Electronic address: Ingrid.Vervuert@vetmed.uni-leipzig.de.
Jazyk: angličtina
Zdroj: Veterinary journal (London, England : 1997) [Vet J] 2011 Nov; Vol. 190 (2), pp. e130-e134. Date of Electronic Publication: 2011 Feb 09.
DOI: 10.1016/j.tvjl.2010.12.032
Abstrakt: Intermittent administration of parathyroid hormone (PTH) is an anabolic therapy for osteoporotic conditions in humans. This study evaluated the effects of equine PTH fragment (ePTH-1-37) administration on bone metabolism in 12 healthy horses. Six horses each were treated once daily for 120days with subcutaneous injections of 0.5μg/kg ePTH-1-37 or placebo. Blood was collected to determine ionized calcium (Ca(++)), total Ca (Ca(T)), inorganic phosphorus, serum equine osteocalcin (eOC), carboxy-terminal telopeptide of type I collagen (ICTP), bone-specific alkaline phosphatase, and carboxy-terminal cross-linked telopeptide of type I collagen. Bone mineral density (BMD) was determined with dual X-ray absorptiometry of the metacarpus and calcaneus. Significantly higher blood Ca(++) and plasma Ca(T) concentrations were measured 5h after ePTH-1-37 administration compared to placebo. Higher serum eOC concentrations were found for ePTH-1-37 treatment at days 90 (P<0.05) and 120 (P=0.05). Significantly higher serum ICTP levels were observed with ePTH-1-37 treatment at days 60 and 90. For both study groups, BMD increased significantly in the calcaneus. Long-term use of ePTH-1-37 seemed to have no negative effects on bone metabolism in healthy horses. The absence of undesirable side effects is the premise to ensure safety for further clinical investigations in horses with increased bone resorption processes.
(Copyright © 2011 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: